Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members. The agreement includes Exagen’s AVISE® Lupus and AVISE® CTD tests making AVISE diagnostic testing available as an in-network benefit.
“Exagen continues to expand its presence within the payor community. The partnership with Evolutions Healthcare Systems will allow their participating health plans the ability to offer AVISE testing as an in-network benefit1 to enable a timely and accurate differential diagnosis to improve outcomes for complex autoimmune diseases, including SLE,” said Ron Rocca, Exagen’s President and CEO.
